BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38402087)

  • 1. Sub-region based radiomics analysis for prediction of isocitrate dehydrogenase and telomerase reverse transcriptase promoter mutations in diffuse gliomas.
    Zhang H; Ouyang Y; Zhang H; Zhang Y; Su R; Zhou B; Yang W; Lei Y; Huang B
    Clin Radiol; 2024 May; 79(5):e682-e691. PubMed ID: 38402087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive L-[methyl-11C] methionine cohort study with two PET scanners.
    Zhou W; Wen J; Huang Q; Zeng Y; Zhou Z; Zhu Y; Chen L; Guan Y; Xie F; Zhuang D; Hua T
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1423-1435. PubMed ID: 38110710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI.
    Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Lei Y; Huang B
    J Magn Reson Imaging; 2023 Nov; 58(5):1441-1451. PubMed ID: 36896953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.
    Peng H; Huo J; Li B; Cui Y; Zhang H; Zhang L; Ma L
    J Magn Reson Imaging; 2021 May; 53(5):1399-1407. PubMed ID: 33179832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status.
    Park YW; Kim S; Park CJ; Ahn SS; Han K; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2022 Dec; 32(12):8089-8098. PubMed ID: 35763095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal MRI-based radiomic nomogram for predicting telomerase reverse transcriptase promoter mutation in IDH-wildtype histological lower-grade gliomas.
    Huo X; Wang Y; Ma S; Zhu S; Wang K; Ji Q; Chen F; Wang L; Wu Z; Li W
    Medicine (Baltimore); 2023 Dec; 102(51):e36581. PubMed ID: 38134061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas.
    Jiang C; Kong Z; Zhang Y; Liu S; Liu Z; Chen W; Liu P; Liu D; Wang Y; Lyu Y; Zhao D; Wang Y; You H; Feng F; Ma W
    Neuroradiology; 2020 Jul; 62(7):803-813. PubMed ID: 32239241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric MRI-based fusion radiomics for predicting telomerase reverse transcriptase (TERT) promoter mutations and progression-free survival in glioblastoma: a multicentre study.
    Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Yang W; Lei Y; Huang B
    Neuroradiology; 2024 Jan; 66(1):81-92. PubMed ID: 37978079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive Prediction of TERT Promoter Mutations in High-Grade Glioma by Radiomics Analysis Based on Multiparameter MRI.
    Tian H; Wu H; Wu G; Xu G
    Biomed Res Int; 2020; 2020():3872314. PubMed ID: 32509858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural- and DTI- MRI enable automated prediction of IDH Mutation Status in CNS WHO Grade 2-4 glioma patients: a deep Radiomics Approach.
    Yuan J; Siakallis L; Li HB; Brandner S; Zhang J; Li C; Mancini L; Bisdas S
    BMC Med Imaging; 2024 May; 24(1):104. PubMed ID: 38702613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas.
    Arita H; Kinoshita M; Kawaguchi A; Takahashi M; Narita Y; Terakawa Y; Tsuyuguchi N; Okita Y; Nonaka M; Moriuchi S; Takagaki M; Fujimoto Y; Fukai J; Izumoto S; Ishibashi K; Nakajima Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Mori K; Ichimura K; Kanemura Y
    Sci Rep; 2018 Aug; 8(1):11773. PubMed ID: 30082856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiomic study on preoperative multi-modal magnetic resonance images identifies IDH-mutant TERT promoter-mutant gliomas.
    Wang H; Zhang S; Xing X; Yue Q; Feng W; Chen S; Zhang J; Xie D; Chen N; Liu Y
    Cancer Med; 2023 Feb; 12(3):2524-2537. PubMed ID: 36176070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T2-FLAIR mismatch sign and machine learning-based multiparametric MRI radiomics in predicting IDH mutant 1p/19q non-co-deleted diffuse lower-grade gliomas.
    Tang WT; Su CQ; Lin J; Xia ZW; Lu SS; Hong XN
    Clin Radiol; 2024 May; 79(5):e750-e758. PubMed ID: 38360515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
    Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
    J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A radiomics feature-based nomogram to predict telomerase reverse transcriptase promoter mutation status and the prognosis of lower-grade gliomas.
    Lu J; Li X; Li H
    Clin Radiol; 2022 Aug; 77(8):e560-e567. PubMed ID: 35595562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
    Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
    Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
    Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
    J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of signal intensity normalization of MRI on the generalizability of radiomic-based prediction of molecular glioma subtypes.
    Foltyn-Dumitru M; Schell M; Rastogi A; Sahm F; Kessler T; Wick W; Bendszus M; Brugnara G; Vollmuth P
    Eur Radiol; 2024 Apr; 34(4):2782-2790. PubMed ID: 37672053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radiomics model based on DCE-MRI and DWI may improve the prediction of estimating IDH1 mutation and angiogenesis in gliomas.
    Wang J; Hu Y; Zhou X; Bao S; Chen Y; Ge M; Jia Z
    Eur J Radiol; 2022 Feb; 147():110141. PubMed ID: 34995947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.